246 related articles for article (PubMed ID: 31312376)
1. Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs.
Wu P; Weng J; Li M; Lu Z; Deng C; Sun Q; Xu R; Geng S; Du X
Am J Transl Res; 2019; 11(6):3651-3658. PubMed ID: 31312376
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.
Hu C; Wang X
Leuk Lymphoma; 2022 Oct; 63(10):2336-2351. PubMed ID: 35543621
[TBL] [Abstract][Full Text] [Related]
3. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Yang L; Wei X; Gong Y
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38146893
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
Ball S; Aguirre LE; Jain AG; Ali NA; Tinsley SM; Chan O; Kuykendall AT; Sweet K; Lancet JE; Sallman DA; Hussaini MO; Padron E; Komrokji RS
Leuk Res; 2023 Jan; 124():106999. PubMed ID: 36542963
[TBL] [Abstract][Full Text] [Related]
7. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.
Della Porta MG; Gallì A; Bacigalupo A; Zibellini S; Bernardi M; Rizzo E; Allione B; van Lint MT; Pioltelli P; Marenco P; Bosi A; Voso MT; Sica S; Cuzzola M; Angelucci E; Rossi M; Ubezio M; Malovini A; Limongelli I; Ferretti VV; Spinelli O; Tresoldi C; Pozzi S; Luchetti S; Pezzetti L; Catricalà S; Milanesi C; Riva A; Bruno B; Ciceri F; Bonifazi F; Bellazzi R; Papaemmanuil E; Santoro A; Alessandrino EP; Rambaldi A; Cazzola M
J Clin Oncol; 2016 Oct; 34(30):3627-3637. PubMed ID: 27601546
[TBL] [Abstract][Full Text] [Related]
8. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.
Chen TC; Hou HA; Chou WC; Tang JL; Kuo YY; Chen CY; Tseng MH; Huang CF; Lai YJ; Chiang YC; Lee FY; Liu MC; Liu CW; Liu CY; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2014 Jan; 4(1):e177. PubMed ID: 24442206
[TBL] [Abstract][Full Text] [Related]
11. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
Hunter AM; Komrokji RS; Yun S; Al Ali N; Chan O; Song J; Hussaini M; Talati C; Sweet KL; Lancet JE; Padron E; List AF; Sallman DA
Blood Adv; 2021 Feb; 5(4):1017-1028. PubMed ID: 33591325
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
Kuendgen A; Müller-Thomas C; Lauseker M; Haferlach T; Urbaniak P; Schroeder T; Brings C; Wulfert M; Meggendorfer M; Hildebrandt B; Betz B; Royer-Pokora B; Gattermann N; Haas R; Germing U; Götze KS
Oncotarget; 2018 Jun; 9(45):27882-27894. PubMed ID: 29963245
[TBL] [Abstract][Full Text] [Related]
13. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract][Full Text] [Related]
15. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
16. Higher
Wang YH; Yao CY; Lin CC; Chen CL; Hsu CL; Tsai CH; Hou HA; Chou WC; Tien HF
EJHaem; 2022 Nov; 3(4):1209-1219. PubMed ID: 36467848
[No Abstract] [Full Text] [Related]
17. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Reidel V; Kauschinger J; Hauch RT; Müller-Thomas C; Nadarajah N; Burgkart R; Schmidt B; Hempel D; Jacob A; Slotta-Huspenina J; Höckendorf U; Peschel C; Kern W; Haferlach T; Götze KS; Jilg S; Jost PJ
Oncotarget; 2018 Apr; 9(25):17270-17281. PubMed ID: 29707107
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
